Buy FOXO4-DRI (Proxofim) Research Peptide
FOXO4-DRI is available as a lyophilised powder, independently HPLC and MS-UPLC tested to ≥98% purity.
Buy FOXO4-DRI (Proxofim) Research Peptide
FOXO4-DRI is available as a lyophilised powder, independently HPLC and MS-UPLC tested to ≥98% purity.
HPLC Verified
≥98% purity
Lyophilised
Powder format
Express Shipping
Cold-chain included
COA Available
Every batch
HPLC Verified
≥98% purity
Lyophilised
Powder format
Express Shipping
Cold-chain included
COA Available
Every batch
Same or Next Day Dispatch
Order before 12pm GMT for same-day dispatch; after 12pm ships next business day
Same or Next Day Dispatch
Order before 12pm GMT for same-day dispatch; after 12pm ships next business day
What is FOXO4-DRI (Proxofim)?
A synthetic cell-penetrating peptide engineered from a fragment of the FOXO4 protein, also known as Proxofim, FOXO4-DRI is studied as a senolytic that clears worn-out cells. Research focuses on how it breaks up the FOXO4-p53 interaction that lingering senescent cells depend on to survive.
- Studied for its disruption of the FOXO4-p53 interaction.
- Investigated in vitro for selective clearance of senescent cells.
- Examined in research models for senolytic activity.
- Used as a research tool to study cellular senescence.
For research use only. Not intended for human use.
Application of D-retro-inverso (DRI) peptidomimetic chemistry to a FOXO4-derived interaction domain produced a 46-amino acid protease-resistant construct that has become a primary research tool in cellular senescence biology. FOXO4-DRI, also designated Proxofim, has an approximate molecular weight of 5400 g/mol. Produced via solid-phase peptide synthesis.
In vitro co-immunoprecipitation and fluorescence polarisation assays have investigated the binding affinity of Proxofim for the p53 interaction domain, examining whether the DRI construct competitively displaces endogenous FOXO4 from the FOXO4-p53 complex in senescent fibroblast cultures. In vivo rodent models have explored the pharmacokinetics and tissue distribution of Proxofim, examining whether the protease-resistant DRI backbone achieves sufficient systemic exposure and tissue penetration.
Manufactured in a quality-controlled laboratory to a guaranteed purity of 98% or above. Every batch undergoes independent third-party testing using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature-controlled, monitored cold storage system. A batch-specific Certificate of Analysis is available on request.
Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.
Scientific Review
Scientific review
Dr. Cristina Cosi
Scientific Contributor and Reviewer
Currently under review
View credentials ›What Researchers Say
Sign in to leave a reviewNo reviews yet. Be the first to share your research experience.
Frequently Asked Questions
Related Compounds
Adipotide
Mol. Wt.
2,611.41 g/mol
Purity
≥98%
CAS No.
N/A (chimeric research peptide)
AOD-9604
Mol. Wt.
1,815.07 g/mol
Purity
≥98%
CAS No.
221231-10-3
SS-31 (Elamipretide)
Mol. Wt.
639.80 g/mol
Purity
≥98%
CAS No.
736992-21-5
PNC-27
Mol. Wt.
4,031.72 g/mol
Purity
≥98%
CAS No.
N/A (novel chimeric research peptide)
NAD+
Mol. Wt.
663.43 g/mol
Purity
≥98%
CAS No.
53-84-9
GDF-8 (Myostatin)
Mol. Wt.
~25,000 g/mol (mature monomer); ~52,000 g/mol (active dimer)
Purity
≥98%
CAS No.
152918-18-8
Select Size
Quality Guaranteed
Every batch is HPLC-tested to ≥98% purity. Certificate of Analysis and SDS available on request.